Imfinzi 120mg Injection Abu Dhabi | Top Pharma Exporter from India

Imfinzi 120mg Injection: Precision PD-L1 Immunotherapy for Oncology Care

Are you searching for a reliable Imfinzi 120 mg injection exporter from India? Ernest Oncology, a dedicated division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced immuno-oncology therapeutics. We serve high-demand healthcare markets in the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, facilitating the international supply of life-saving biologics through a secure, cold-chain pharmaceutical network.

Detailed Product Overview: What is Imfinzi 120mg?

Imfinzi 120 mg is a sterile, preservative-free solution containing the active monoclonal antibody Durvalumab. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody produced by recombinant DNA technology. While the 500mg vial is used for higher dose requirements, the 120mg/2.4mL vial is essential for precise weight-based dosing and pediatric or maintenance protocols.

By targeting the PD-L1 pathway, Imfinzi 120 mg restores the ability of the patient's immune system to detect and destroy cancer cells. It is a cornerstone treatment for several aggressive malignancies, particularly in the lungs and biliary tract.

Primary Therapeutic Indications:

Imfinzi 120 mg is clinically indicated for the following:

• Non-Small Cell Lung Cancer (NSCLC): For adult patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

• Small Cell Lung Cancer (SCLC): Used as a first-line treatment for extensive-stage SCLC in combination with chemotherapy.

• Biliary Tract Cancer (BTC): In combination with chemotherapy for locally advanced or metastatic BTC.

• Hepatocellular Carcinoma (HCC): Part of a combination regimen for adult patients with unresectable HCC.

Mechanism of Action: How Imfinzi Works:

Imfinzi functions as an "Immune Checkpoint Inhibitor" that targets the PD-L1 protein.

1. Checkpoint Blockade: Cancer cells often express PD-L1 (Programmed Cell Death Ligand-1) to evade the immune system. When PD-L1 binds to PD-1 on T-cells, it sends an "off" signal.

2. Binding Specificity: Durvalumab binds specifically to PD-L1, preventing it from interacting with both PD-1 and CD80.

3. Immune Reactivation: By blocking these inhibitory signals, Imfinzi "releases the brakes" on the immune system, enabling the patient’s T-cells to identify, attack, and kill malignant cells.

Administration and Dosage:

• Route: Administered as an Intravenous (IV) Infusion by a qualified oncology professional.

• Vial Strength: The 120 mg/2.4 mL vial allows for granular dosing adjustments based on the patient's body weight or specific clinical cycle requirements.

• Storage: Requires strict cold-chain management (2°C to 8°C) from the Indian facility to the destination country to maintain biological activity.

Safety Profile & Side Effects:

As an immunotherapy, Imfinzi can cause immune-mediated adverse reactions. Healthcare providers monitor for:

• Immune-Mediated Organ Inflammation: Including pneumonitis, colitis, and hepatitis.

• Endocrinopathies: Potential changes in thyroid, adrenal, or pituitary gland function.

• Infusion-Related Reactions: Monitoring during the infusion process.

• Common Symptoms: Cough, fatigue, hair loss (when used with chemo), and nausea.

Why source Imfinzi 120 mg from Ernest Oncology?

• Biologic Cold Chain Expertise: Immunotherapies require absolute temperature integrity. We ensure validated thermal packaging for export to the USA, UK, UAE, Australia, and South Africa.

• Authenticity Guaranteed: Direct procurement from GMP-certified facilities, maintaining the integrity of every exporter from India shipment.

• Bulk Availability: Consistent inventory of both 120mg and 500mg vials to prevent treatment gaps in international hospital settings.

• B2B Documentation: We provide comprehensive documentation, including COAs and export permits for seamless customs clearance.